Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 11/20 | 0.74 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.74 |
| ▸ | MAPK8 | P45983 | 10/20 | 0.74 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.42 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6376886 | 0.86 | MAPK10 (0.71) | MAPK10MAPK14MAPK8MAP2K4ITK | |
| SCHEMBL6422935 | 0.85 | MAPK8 (1.00) | MAPK10MAPK14MAPK8 | |
| SCHEMBL6378540 | 0.84 | MAPK10 (0.69) | MAPK10MAPK14MAPK8MAP2K4 | |
| SCHEMBL6371467 | 0.84 | MAPK10 (0.72) | MAPK10MAPK14MAPK8MAP2K4ALK | |
| SCHEMBL6370442 | 0.83 | MAPK8 (0.90) | MAPK10MAPK14MAPK8 | |
| SCHEMBL6371272 | 0.83 | MAPK10 (0.68) | MAPK10MAPK14MAPK8MAP2K4ALK | |
| Hydrochloric Acid SCHEMBL6370416 | 0.80 | MAPK10 (0.98) | MAPK10MAPK14MAPK8MAP2K4 | |
| Hydrochloric Acid SCHEMBL6370142 | 0.80 | MAPK10 (0.77) | MAPK10MAPK14MAPK8FLT3MAP2K4 | |
| SCHEMBL6371425 | 0.78 | MAPK8 (1.00) | MAPK10MAPK14MAPK8 | |
| SCHEMBL6375883 | 0.77 | MAPK8 (0.90) | MAPK10MAPK14MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113370-A1 | Therapeutic substituted indazole derivatives | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | US | claimed |
| EP-1476432-A1 | THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2004-11-17 | — | — | EP | claimed |
| WO-2003068754-A1 | THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | WO | claimed |
| US-20050113370-A1 | Therapeutic substituted indazole derivatives | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | US | disclosed |
| EP-1476432-A1 | THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068754-A1 | THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113370-A1 | Therapeutic substituted indazole derivatives | NR4A3, CBR3, NR3C2 | MAPK10 2059/4885MAPK14 2226/4885MAPK8 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.